Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian M Shuch

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Molecular Pharmacology|June 9, 2019
Inhibition of Heat Shock Protein 90 suppresses TWIST1 TranscriptionKay Yi Chong, Min Kang, Francesca Garofalo, et al.
Nature|June 5, 2020
Oncometabolites suppress DNA repair by disrupting local chromatin signallingParker L Sulkowski, Sebastian Oeck, Jonathan Dow, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2025
SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass CharacterizationSteven P Rowe, Brian M Shuch, Mark W Ball, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc|July 16, 2021
Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary PerspectiveAsser M Abou Elkassem, Simon S Lo, Andrew J Gunn, et al.
JAMA Network Open|August 6, 2024
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical TrialShuchi Gulati, Catherine Tangen, Christopher W Ryan, et al.
Oncogenesis|May 31, 2020
Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cellsMin Kang, Kay Yi Chong, Tobias M P Hartwich, et al.
BJU International|July 17, 2024
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinomaAbhishek Tripathi, Catherine M Tangen, Melissa Plets, et al.
The Journal of Urology|April 7, 2020
Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II TrialDaniel M Geynisman, Brian T Kadow, Brian M Shuch, et al.
The Journal of Urology|June 24, 2020
Reply by AuthorsDaniel M Geynisman, Brian T Kadow, Brian M Shuch, et al.
Lancet (London, England)|July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trialChristopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Molecular Pharmacology|June 9, 2019
Inhibition of Heat Shock Protein 90 suppresses TWIST1 TranscriptionKay Yi Chong, Min Kang, Francesca Garofalo, et al.
Nature|June 5, 2020
Oncometabolites suppress DNA repair by disrupting local chromatin signallingParker L Sulkowski, Sebastian Oeck, Jonathan Dow, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2025
SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass CharacterizationSteven P Rowe, Brian M Shuch, Mark W Ball, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc|July 16, 2021
Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary PerspectiveAsser M Abou Elkassem, Simon S Lo, Andrew J Gunn, et al.
JAMA Network Open|August 6, 2024
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical TrialShuchi Gulati, Catherine Tangen, Christopher W Ryan, et al.
Oncogenesis|May 31, 2020
Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cellsMin Kang, Kay Yi Chong, Tobias M P Hartwich, et al.
BJU International|July 17, 2024
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinomaAbhishek Tripathi, Catherine M Tangen, Melissa Plets, et al.
The Journal of Urology|April 7, 2020
Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II TrialDaniel M Geynisman, Brian T Kadow, Brian M Shuch, et al.
The Journal of Urology|June 24, 2020
Reply by AuthorsDaniel M Geynisman, Brian T Kadow, Brian M Shuch, et al.
Lancet (London, England)|July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trialChristopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
Pageof 4